

To,

National Stock Exchange of India Limited

Exchange Plaza, Bandra - Kurla Complex,

Bandra (East), Mumbai-400 051

Dated: 5th May, 2020

To,

P. J. Towers, Dalal Street, Fort

Mumbai - 400 001

BSE Limited

Ref.: BSE Scrip Code No. "533138" **Ref.:** "ASTEC"

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 5th May, 2020 (which commenced at 4.00 p.m. and concluded at 5.50 p.m.), *inter alia*, has approved / noted the following:-

- (a) Upon recommendation of the Audit Committee, the Board of Directors has approved the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31st March, 2020 along with Cash Flow Statement and the Statement of Assets and Liabilities as on 31st March, 2020 (enclosed herewith).
- (b) Upon recommendation of the Audit Committee, took note of the Statutory Auditors' Report on the Audited Financial Results (Standalone & Consolidated) for the Quarter and Financial Year ended 31st March, 2020 (enclosed herewith).
 - The Report of Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended 31st March, 2020.
- (c) Recommended Final Dividend of 15% (Fifteen per cent) on the Equity Share Capital of the Company, i.e., Rs.1.50 (Rupee One and Paise Fifty) per Equity Share of Face Value of Rs.10/-(Rupees Ten Only) each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th (Twenty Sixth) Annual General Meeting of the Company.
- (d) Considered and fixed the date of the 26th (Twenty Sixth) Annual General Meeting and related matters as under:-
 - (i) The 26th (Twenty Sixth) Annual General Meeting of the Shareholders of the Company will be held on Wednesday, 22nd July, 2020 at 4.00 p.m. at the "Auditorium", Godrej One, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai 400079, Maharashtra.









CIN: L99999MH1994PI C076236



- (ii) The Book Closure Dates for the purposes of the 26^{th} (Twenty Sixth) Annual General Meeting and payment of Final Dividend are from Saturday, 18^{th} July, 2020 to Tuesday, 21^{st} July, 2020. The dividend will be paid by Friday, 31^{st} July, 2020.
- (iii) The Register of Members and Share Transfer Books will remain closed from Saturday, 18th July, 2020 to Tuesday, 21st July, 2020.
- (e) The Board of Directors has amended the Code of Conduct for Prevention of Insider Trading of the Company.
- (f) Re-appointment of Mr. Vijay Kashinath Khot and Dr. Brahma Nand Vyas as the "Independent Directors" of the Company Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("said Regulations") read with Para A of Part A of Schedule III to the said Regulations:

The Board of Directors has, upon the recommendation of the Nomination and Remuneration Committee of the Board of Directors of the Company, re-appointed Mr. Vijay Kashinath Khot and Dr. Brahma Nand Vyas as the "Independent Director" of the Company for a further period of 5 (five) years commencing from 29th January, 2021 upto 28th January, 2026, subject to approval of the Shareholders at the ensuing Annual General Meeting of the Company and other approval(s), as may be required.

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("said Regulations") read with Para A of Part A of the Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given hereunder:-

Sr.	Disclosure Requirement	Mr. Vijay Kashinath Khot	Dr. Brahma Nand Vyas
No.			
1.	Reason for Change, viz.,	The present term of Mr.	The present term of Dr.
	appointment, resignation,	Vijay Kashinath Khot as an	Brahma Nand Vyas as an
	removal, death or otherwise	"Independent Director" of	"Independent Director" of
		the Company is expiring on	the Company is expiring on
		28 th January, 2021. The	28 th January, 2021. The
		Board of Directors has	Board of Directors has
		granted approval for his re-	granted approval for his re-
		appointment as an	appointment as an
		"Independent Director" of	"Independent Director" of
		the Company for a further	the Company for a further
		period of 5 (Five) years	period of 5 (Five) years
		commencing from 29 th	commencing from 29 th
		January, 2021 upto 28 th	January, 2021 upto 28 th
		January, 2026, for a second	January, 2026, subject to







CIN: L99999MH1994PI C076236



		term, subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company and	in the ensuing Annual General Meeting of the Company and other
		other approval(s), as may be required.	approval(s), as may be required.
2.	Date of appointment / cessation (as applicable) and term of appointment	Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 5 th May, 2020, has re-appointed Mr. Vijay Kashinath Khot as the "Independent Director" of the Company for a further period of 5 (Five) years commencing from 29 th January, 2021 upto 28 th January, 2021 upto 28 th January, 2026, for a second term, subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company and other approval(s), as may be required.	Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 5 th May, 2020, has re-appointed Dr. Brahma Nand Vyas as the "Independent Director" of the Company for a further period of 5 (Five) years commencing from 29 th January, 2021 upto 28 th January, 2026, for a second term, subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company and other approval(s), as may be required.
3.	Brief Profile (in case of appointment)	Mr. Vijay Kashinath Khot, aged 70 years, is Science Graduate from the University of Mumbai and was associated with Godrej Group from September 1973 till 2011. He has worked in Animal Feeds for 26 years in the State of Gujarat and was also instrumental in introducing Godrej Agri Products in the said State in the year 1986. Since the year	Dr. Brahma Nand Vyas, aged 70 years, has completed graduation B.Sc. Agriculture in 1971 from the University of Rajasthan, Jaipur and Post-Graduation M.Sc. Agriculture with Honours in Soil Science and Agricultural Chemistry in 1973 from the University of Udaipur, Rajasthan. He worked with Bhabha Atomic Research Centre (BARC) Trombay, since 1974 till 1987, and then joined Godrej Soaps Limited.







and

first

first

has

including

based



2000, he was associated with He obtained Doctorate in 1980, while in service in Poultry business and was Chemistry from University of looking after the sales of Gujarat, Ahmedabad. Real Good Chicken (RGC) BARC, Dr. Vyas worked on mainly in the metro cities of the Behaviroural aspects of Mumbai, Pune, Bangalore, most Toxic Radionuclides Chennai and Hyderabad. He Plutonium -239 was also a Director of Bahar Americium-241 in soils and Soil-Plant systems. Agrochem And Feeds Limited, Goldmuhor At Godrej Soaps Limited Agrochem & Feeds Limited initially and later at Godrej and Anamudi Real Estates Agrovet Limited, he led R&D Limited. As a trainer, he for nearly two decades, and imparts training to sales was responsible for the development and Launch of personnel in his professional first ever Commercial Neem capacity. based Urea Coating Agent, country's Registered Neem Insecticide, the world's Homobrassinolide Growth Promoters for grapes initially and later for other crops, and most recently very Unique Post Emergence Selective Herbicide Cotton, based on Pyrithiobac sodium. During the R&D assignments, he published more than 60 scientific publications International and National Journals of High repute, besides presentations

4. Disclosure of relationships between the Directors (in case of appointment of Director)

Mr. Vijay Kashinath Khot is not related to any other Director of the Company.

Dr. Brahma Nand Vyas is not related to any other Director of the Company.

international patents.

International Seminars. He is the holder of more than 25

patents











Further, this is to confirm that Vijay Kashinath Khot and Dr. Brahma Nand Vyas are not debarred from holding the office of Director by virtue of any order of the Securities and Exchange Board of India (SEBI) or any other such authority.

Please take the above information on your records.

Thanking you,

Yours sincerely,
For Astec LifeSciences Limited

Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167)

Encl.: As above









Corporate Identity Number: L99999MH1994PLC076236



Registered Office: Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai-400079, Maharashtra Website: www.astecls.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Audited Standalone Financial Results for the Quarter and Year ended 31st March, 2020

Rs. in Lakh (Except per Equity Share data)

No. Particulars			STANDALONE				
Sr. No							Ended
Revenue from Operations 18,018.43 12,483.36 13,375.79 52,222.09 43,090.12	Sr. No	Particulars	31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
Revenue from Operations			(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Other Income			, ,	, ,	` ′	,	`
Total Income (I+II) Expenses 18,542.58 12,876.45 13,949.83 53,415.34 44,200.19	I	Revenue from Operations	18,018.43	12,483.36	13,375.79	52,222.09	43,090.12
Expenses 10,117,40 9,015.27 6,431.98 33,343.71 29,505.18	II	Other Income	524.15	393.09	574.04	1,193.25	1,110.07
Cost of materials consumed 10,117.40 9,015.27 6,431.98 33,343.71 29,505.18 Changes in inventories of finished goods, stock-in-trade and work-in-progress 1,066.10 (1,002.22) 2,819.82 472.50 (1,555.88) 1,559.88 1,666.05 746.65 565.55 2,992.04 2,509.88 1,666.05 746.65 565.55 2,992.04 2,509.88 7,666 7,666 7,667 7,67 7,7 7,	III	Total Income (I+II)	18,542.58	12,876.45	13,949.83	53,415.34	44,200.19
Changes in inventories of finished goods, stock-in-trade and work-in-progress 1,066.10 (1,002.22) 2,819.82 472.50 (1,555.88) Employee benefits expense 860.05 746.65 565.55 2,992.04 2,509.88 2,50	IV	Expenses					
Employee benefits expense			10,117.40	9,015.27	6,431.98	33,343.71	29,505.18
Finance costs 215.99 339.38 315.17 1,263.88 1,237.59 1,259.15 1,259.15 1,259.15 1,259.16 1,259.16 1,259.20		Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)
Depreciation and amortisation expense 616.37 579.15 547.46 2,322.38 1,934.06		Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88
Other expenses (Refer note 7)		Finance costs	215.99	339.38	315.17	1,263.88	1,237.59
Total expenses (IV)		Depreciation and amortisation expense	616.37	579.15	547.46	2,322.38	1,934.06
Profit / (loss) before exceptional items and tax (III - IV) 3,961.12 1,559.12 2,017.76 6,127.42 5,579.33 VII Exceptional Items		Other expenses (Refer note 7)	1,705.55	1,639.10	1,252.09	6,893.41	4,990.03
Exceptional Items		Total expenses (IV)	14,581.46	11,317.33	11,932.07	47,287.92	38,620.86
VII	V	Profit / (loss) before exceptional items and tax (III - IV)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33
VIII	VI	Exceptional Items	-	-	-	-	-
(1) Current tax (2) Deferred tax (2) Deferred tax (3) Tax for earlier years (3) Tax for earlier years (3) Profit / (loss) from the period from continuing operations (VII-VIII) (3) Tax expense of discontinued operations (4) Tax expense of discontinued operations (5) Tax expense of discontinued operations (6) Tax expense of discontinued operations (7) Tax expense of discontinued operations (8) Tax expense of discontinued operations (9) Tax expense of discontinued operations (10) Tax expense of discontinued operations (11) Tax expense of discontinued operations (12) Tax expense of discontinued operations (13) Tax expense of discontinued operations (14) Tax expense of discontinued operations (15) Tax expense of discontinued operations (16) Tax expense of discontinued operations (17) Tax expense of discontinued operations (18) Tax expense of discontinued oper	VII	Profit / (loss) before tax (V + VI)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33
(2) Deferred tax (3) Tax for earlier years (4) Profit / (loss) for the period from continuing operations (VII-VIII) (5) Profit / (loss) for the period from continuing operations (VII-VIII) (6) Tax expense of discontinued operations (7) Tax expense of discontinued operations (8) Tax expense of discontinued operations (8) Tax expense of discontinued operations (8) Tax expense of discontinued operations (9) Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) (10) Tax expense of discontinued operations (11) Tax expense of discontinued operations (12) Tax expense of discontinued operations (13) Tax for earlier years (14) Tax expense of discontinued operations (14) Tax expense of discontinued operations (15) Tax expense of discontinued operations (15) Tax expense of discontinued operations (17) Tax expense of discontinued operations (18) Tax expe	VIII	Tax Expense:					
Comprehensive Income Comprehensive Income for the period (XIII + XIV) (Comprising Compr		(1) Current tax	1,047.74	402.48	472.87	1,605.78	1,528.88
IX Profit / (loss) for the period from continuing operations (VII-VIII) 3,116.62 1,215.42 1,269.93 4,747.19 3,568.60 X Profit / (loss) from discontinued operations		(2) Deferred tax	(203.24)	(74.38)	244.91	(305.49)	442.22
X Profit / (loss) from discontinued operations - - - - - - - - -		(3) Tax for earlier years	-	15.60	30.05	79.94	39.63
XI	IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60
Note	X	Profit / (loss) from discontinued operations	-	-	-	-	-
XIII Profit / (loss) for the period (IX + XII) 3,116.62 1,215.42 1,269.93 4,747.19 3,568.60 XIV Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss (19.31) (1.68) 3.80 (24.34) (6.70) (ii) Income tax relating to items that will not be reclassified to profit or loss 4.87 0.42 (1.33) 6.13 2.34 B (i) Items that will be reclassified to profit or loss - 49.18 - 35.25 (ii) Income tax relating to items that will be reclassified to profit or loss - (17.07) - (12.20) XV Total Comprehensive Income for the period (XIII + XIV) (Comprising 70 10 10 10 10 Profit / (loss) and Other Comprehensive Income for the period) 3,102.18 1,214.16 1,304.51 4,728.98 3,587.29	XI	Tax expense of discontinued operations	-	-	-	-	-
XIV Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) 3.80 (24.34) (6.70) (1.33) 6.13 2.34 (17.07) - (12.20) 3.52.5 (17.07) - (12.20) 3.102.18 1,214.16 1,304.51 4,728.98 3,587.29	XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) (19.31) (1.68) 3.80 (24.34) (6.70) 4.87 0.42 (1.33) 6.13 2.34 3.52.5 (17.07) - (12.20) 3.102.18 1,214.16 1,304.51 4,728.98 3,587.29	XIII	Profit / (loss) for the period (IX + XII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60
(ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) 3,102.18 4.87 0.42 (1.33) 6.13 2.34 4.71.07 - (12.20) 3,102.18 1,214.16 1,304.51 4,728.98 3,587.29	XIV						
B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) 35.25 (17.07) - (12.20) 3,102.18 1,214.16 1,304.51 4,728.98 3,587.29			(19.31)	(1.68)		(24.34)	
(ii) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) 3,102.18 1,214.16 1,304.51 4,728.98 3,587.29		(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period) 3,102.18 1,214.16 1,304.51 4,728.98 3,587.29			-	-		-	35.25
Profit / (loss) and Other Comprehensive Income for the period) 3,102.18		(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)
	XV		3,102.18	1,214.16	1,304.51	4,728.98	3,587.29
	XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27
XVII Other Equity excluding Revaluation Reserve 22,687.06 18,291.22				·	·		
Fornings per equity share (Face Value of Ps. 10/ per share) (for continuing &						,	, .
XVIII discontinued operations) (non-annualised):	XVIII						
(1) Basic (in Rs.) 15.94 6.21 6.50 24.27 18.26			15.94	6.21	6.50	24.27	18.26
(2) Diluted (in Rs.) 15.93 6.21 6.49 24.25 18.23			15.93		6.49		I

Notes:

- 1 The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
 - In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

ASHOK VISHWANATH HIRENMATH

Ashok Hiremath **Managing Director** DIN:-00349345 Tuesday, 5th May, 2020, Mumbai

Digitally signed by **BURJIS** BURJIS TEHMURASP TEHMURASP PARDIWALA PARDIWALA Date: 2020.05.05 17:31:53 +05'30'



Corporate Identity Number: L99999MH1994PLC076236



Registered Office: Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra Website: www.astecls.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com Statement of Audited Consolidated Financial Results for the Quarter and Year ended 31st March, 2020

Rs. in Lakh (Except per Equity Share data)

RS, II LAI CONSOLIDAT					ED Equity Share data)		
		Quarter Ended Year Ended					
Sr. No	Particulars Particulars	31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19	
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
I	Revenue from Operations	18,056.95	12,483.36	13,375.79	52,260.61	43,090.12	
II	Other Income	524.15	393.09	575.94	1,193.25	1,115.66	
III	Total Income (I+II)	18,581.10	12,876.45	13,951.73	53,453.86	44,205.78	
IV	Expenses						
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18	
İ	Purchase of Stock-in-Trade	37.07	-	-	37.07	-	
ĺ	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)	
İ	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88	
ĺ	Finance costs	214.88	338.27	315.17	1,259.43	1,237.59	
ĺ	Depreciation and amortisation expense	614.88	577.66	547.68	2,316.42	1,934.94	
	Other expenses (Refer note 7)	1,707.45	1,639.81	1,249.97	6,897.44	4,983.66	
	Total expenses (IV)	14,617.83	11,315.44	11,930.17	47,318.61	38,615.37	
V	Profit / (loss) before exceptional items and tax (III - IV)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41	
VI	Exceptional Items	-		<u> </u>	-	-	
VII	Profit / (loss) before tax (V + VI)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41	
VIII	Tax Expense:			·		·	
	(1) Current tax	1,048.07	402.90	473.69	1,607.40	1,530.88	
	(2) Deferred tax	(203.01)	(74.22)	245.20	(304.80)	442.94	
	(3) Tax for previous years	` <u>-</u> ′	15.60	30.05	79.94	40.05	
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54	
X	Profit / (loss) from discontinued operations	-	-	-	-	-	
XI	Tax expense of discontinued operations	-	-	-	-	-	
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	
XIII	Profit / (loss) for the period (IX + XII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54	
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34	
	B (i) Items that will be reclassified to profit or loss	1.26	(0.73)	49.15	1.15	36.01	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)	
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit	3,105.03	1,214.74	1,307.17	4,735.65	3,595.99	
AV	/ (loss) and Other Comprehensive Income for the period)	3,103.03	1,214.74	1,507.17	4,733.03	3,393.99	
XVI	Net Profit/(loss) attributable to:						
	- Owners	3,117.61	1,216.39	1,271.78	4,751.11	3,573.68	
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86	
	Total Comprehensive Income attributable to:						
	- Owners	3,104.43	1,214.40	1,306.33	4,734.05	3,593.13	
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86	
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27	
XVIII	Other Equity excluding Revaluation Reserve				22,699.74	18,293.38	
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing &						
AIA	discontinued operations) (non-annualised) :						
	(1) Basic (in Rs.)	15.94	6.22	6.50	24.29	18.28	
	(2) Diluted (in Rs.)	15.93	6.21	6.50	24.27	18.26	

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company
- 6 In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
- In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

ASHOK Digitally signed by ASHOK VI DN: c+IN. o+Personal VISHWANATH HIRENMATH

Ashok Hiremath **Managing Director** DIN :- 00349345 Tuesday, 5th May, 2020, Mumbai

BURJIS TEHMURASP PARDIWALA PARDIWALA Date: 2020.05.05 17:32:19 +05'30'

Digitally signed by BURJIS TEHMURASP





Corporate Identity Number : L99999MH1994PLC076236 Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra Website: www.astecls.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com Statement of Cash Flows for the Year ended 31st March, 2020

	STANDA	CONSOLIDATED			
	Year En		Year Ended		
PARTICULARS	31-Mar-20	31-Mar-19	31-Mar-20	31-Mar-19	
	(Audited)	(Audited)	(Audited)	(Audited)	
Cash flow from operating activities					
Profit before tax	6,127.42	5,579.33	6,135.25	5,590.	
Adjustments for					
Depreciation and amortisation expense	2,321.89	1,934.06	2,316.42	1,934	
Interest income	(26.56)	(36.28)	(26.56)	(36	
Finance cost	1,263.88	1,237.59	1,259.43	1,237	
Unrealised foreign exchange (gain)/loss	142.74	(189.76)	143.89	(189	
Loss allowance	31.14	3.58	31.14	3	
Loss/(Gain) on sale of property, plant and equipment	17.96	(0.04)	17.96	(0	
Bad debts / advances written off	-	242.54	-	242	
Employee stock options expense	5.55	16.35	5.55	16	
Net loss / (Gain) on lease modification	0.48	-	-		
Sundry balances written back	-	(174.75)	-	(174	
·	3,757.08	3,033.29	3,747.83	3,034	
Operating Profit Before Working Capital Changes	9,884.50	8,612.62	9,883.08	8,625	
Change in operating assets and liabilities					
(Increase)/Decrease in trade receivables	(3,437.45)	(102.89)	(3,437.53)	(102	
(Increase)/Decrease in loans	1.77	(52.85)	1.77	(52	
(Increase)/Decrease in other financial assets-current	(430.63)	91.08	(430.63)	91	
(Increase)/Decrease in other current assets	1,741.49	(431.51)	1,741.69	(431	
(Increase)/Decrease in inventories	(2,832.11)	(1,437.12)	(2,832.11)	(1,437	
(Increase)/Decrease in other non-current assets	38.40	(12.77)	38.40	(12	
Increase/(Decrease) in trade payables	13,124.53	(3,514.01)	13,115.25	(3,554	
Increase/(Decrease) in other financial liabilities	547.45	19.37	547.15	52	
Increase/(Decrease) in other current liabilities	35.44	8.99	35.91	2	
Increase/(Decrease) in provisions	2.76	(7.90)	2.76	(7	
Cash generated from operations	18,676.15	3,173.01	18,665.74	3,171	
Direct Taxes paid (net of refunds received)	(1,820.03)	(1,640.51)	(1,821.68)	(1,642	
Net cash inflow / (outflow) operating activities	16,856.12	1,532.50	16,844.06	1,528	
Cash flow from investing activities					
Acquisition of property, plant and equipment & cwip	(4,529.40)	(5,277.54)	(4,529.40)	(5,277	
Proceeds from sale of property, plant and equipment	15.75	1.61	15.75	1	
Intercorporate deposits given	(2,886.52)		(2,886.52)		
Deposits redeemed / (placed)	10.98	(10.27)	10.98	(10	
Interest received	8.12	36.28	8.12	36	
Net cash inflow / (outflow) investing activities	(7,381.07)	(5,249.92)	(7,381.06)	(5,249	
Cash flow from financing activities					
Proceeds / (Repayment) of borrowings (net)	(7,830.73)	5,272.93	(7,830.73)	5,272	
Proceeds from issue of shares	21.96	27.60	21.96	27	
Payment of lease liabilities	(10.80)	27.00	-	2,	
Finance cost	(1,291.03)	(1,237.59)	(1,291.03)	(1,237	
Dividend paid to company's shareholders (including Dividend	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(1,237.37)			
Distribution Tax)	(353.63)	(353.45)	(353.63)	(353	
Net cash inflow (outflow) from financing activities	(9,464.23)	3,709.49	(9,453.43)	3,709	
Net increase / (decrease) in cash and cash equivalents	10.82	(7.93)	9.58	(11	
vet increase / (decrease) in easi and easi equivalents		24.37	21.23	33	
Cook and each equivalents as at the beginning of the year					
Cash and cash equivalents as at the beginning of the year Cash and cash equivalents as at the end of the year	16.44 27.26	16.44	30.81	21	

ASHOK Digitally significant of the control of the c HIRENMATH

SerialNumbers ad 2
bbc/97b7949c5272
c67e, cn=485b5.51

BURJIS Digitally signed by BURJIS TEHMURASP PARDIWALA Date: 2020.05.05 17:32:44 +05'30'



Astec LifeSciences Limited Corporate Identity Number: L99999MH1994PLC076236



Registered Office: Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai-400079, Maharashtra
Website: www.astecls.com, Tel no..022-25195768, Fax no.. 022-22618289, Email id: astecinfo@godrejastec.com
Statement of Assets and Liabilities as at 31st March, 2020

(Rs.	in	Lakh

(a) Property, Plart and Equipment (17,747-43) 16,487-64 17,777-240 16,488-25 (b) Capital work-an-progress 2,211.2 18,65.2 4 2,211.2 18,65.2 (c) Investment property (1.43.17 2 1.43.18 2 1.43.18 2 1.43.18 2 1.43.18 2 1.43.18 2 1.43.18 2 1.43.18 2 1.43.18 2		STAND	ALONE	CONSO	(Rs. in Lakh)
March Marc					
ASSETS Non-current assets Asset	<u>PARTICULARS</u>				
ASSIS 10 Non-current assets 17,747.43 16,457.64 17,772.24 16,488.25 16,000 16,488.25 18,000					
(a) Property, Plart and Equipment (b) Capial work—properes (c) Expland work—properes (c) Right of fuse (d) Other Intrangible assets (d) Other Intrangible assets (d) Other Intrangible assets (e) Intrangible assets under development (d) Other Intrangible assets under development (e) Intrangible assets under development (f) Investments in Subsidiares (g) Financial Assets (g) Financial As	<u>ASSETS</u>	,	, ,	, ,	,
(b) Capital work-in-progres (c) Right of use (d) Other International Sasets (e) International Sasets (e) International Sasets (e) International Sasets (e) International Sasets (f) Differ International Sasets (g) Biological Assets other than better plants (e) Financial Assets other than better plants (f) Investments in Subsidiaries (g) Financial Assets other than better plants (ii) Investments (iii) Index receivables (iii) Index receivables (iii) Index receivables (iii) Index assets (net) (iii) Deferred assets (iii) Other Tax assets (net) (i) Other Tax assets (net) (i) Other International Sasets (iii) Other International	(1) Non-current assets				
(c) Investment property (d) Other Intangible assets (15 Right of use (d) Other Intangible assets (15 Right of use (d) Other Intangible assets (15 Right of use (d) Other Intangible assets (d) Biological Assets other development (e) Intangible assets under development (f) Investments in Subsidiaries (d) Investments in Subsidiaries (e) Intangible assets under development (f) Investments in Subsidiaries (g) Financial Assets (ii) Investments (iii) Investments (iii) Loans (iii) Coans (iiii) Coans (iii) Coans (iii) Coans (iiii) Coans (iii) Coans (iii) Coans ((a) Property, Plant and Equipment	17,747.43	16,457.64	17,772.40	16,488.23
(c) Right of use	(b) Capital work-in-progress	2,211.22	1,863.24	2,211.22	1,863.24
(d) Other Intamgable assets (e) 1 Intamgable assets under development 199.52 3.474 199.52 3.474 (g) Biological Assets other than bearer plants 199.52 3.474 199.52 3.474 (g) Biological Assets other than bearer plants 199.52 3.474 199.52 3.474 (g) Biological Assets other than bearer plants 199.52 3.474 199.52 3.474 (g) Biological Assets other than bearer plants 199.52 3.48 18.89	(c) Investment property	-	_	-	-
(c) Intrangible assets under devolopment (g) Biological Assets of the man bearer plants (c) Investments in subsidiaries (d) Investments in Subsidiaries (e) Investments e) Investment (e) Investmen	(c) Right of use	1,463.75	_	1,433.17	_
(g) Biological Assets other than bearer plants (f) Investments in Subsidiaries (a) Francial Assets (b) Investments in Subsidiaries (c) Investments (d) Investments (e) Investment (e) Inve	(d) Other Intangible assets	156.86	206.71	156.86	206.71
(i) Investments in subsidiaries (g) Financial Assets (ii) Investments (ii) Investments (ii) Investments (ii) Investments (iii) Others (iii) Others (iii) Others (iii) Others (iii) Others (iii) Other Investments (iii) Other Investments (iii) Other Investments (iii) Investment (iii) Investments (iii) Investment (iiii) Investment (iii) Investment (iii) Investment (iii) Investment	(e) Intangible assets under development	199.52	34.74	199.52	34.74
(g) Francial Assets (i) Invastments (ii) Loans (iii) Loans (iii) Loans (iii) Loans (iii) Loans (iii) Loans (iii) Colors (iiii) Colors (iiii) Colors (iii) Colors	(g) Biological Assets other than bearer plants	-	-	-	-
(i) Investments (ii) Trade receivables (iii) Colors (iii) Color (iii) Colors (iii) Others (iii) Other (iii) Color	(f) Investments in Subsidiaries	48.89	48.89	-	-
(ii) Trade receivables (iii) Lomas (iii) Lomas (iii) Comman (iii) Comman (iii) Comman (iii) Comman (iii) Comman (iii) Comman (iii) Comman (iii) Trade Receivables (iii) Deferred tax assets (net) (i) Other non-current assets (ii) Investments (iii) Trade Receivables (iii) Trade Receivables (iii) Cash and cash equivalents (iii) Trade Receivables (iii) Cash and cash equivalents (iv) Comman Machanic Sorberthan (iii) above (iii) Cash and cash equivalents (iv) Comman Machanic Sorberthan (iii) above (iii) Cash and cash equivalents (iv) Other current assets (iii) Other current assets (iii) Other current assets (iv) Oth	(g) Financial Assets				
(a) 1 Loans (b) Others (c) Other Tax assets (net) (d) Other Ida assets (net) (e) Other Tax assets (net) (e) Other Tax assets (net) (e) Other Tax assets (net) (e) Other Tax assets (net) (e) Other Ida assets (net) (e) Other Ida assets (net) (f) Total Non-current assets (a) Inventories (b) Financial Assets (c) Investments (e) Financial Assets (f) Investments (g) Trade Receivables (g) Other Current assets (h) Investments (g) Trade Receivables (g) Other Current assets (h) Investments (g) Trade Receivables (g) Other Current assets (h) Investments (h) Other Current assets (h) Investments (h) Other Current assets (h) Other Current Idabilities (h) Other Current Liabilities	(i) Investments	0.53	0.53	0.53	0.53
(ii) Others (b) Other Tax assets (net) (b) Other Tax assets (net) (c) Other non-current assets (net) (c) Other non-current assets (net) (c) Other non-current assets (net) (c) Other non-current assets (net) (c) Other non-current assets (net) (c) Other non-current assets (net) (d) Other non-current assets (net) (d) Other non-current assets (net) (d) Other non-current assets (d) Inventories (d) Financial Labilities (d) Financial Labilities (d) Financial Labilities (e) Financial Labilities (d) Financial Labilities (e) Financial Labilities (e) Financial Labilities (d) Financial Labilities (e) F	(ii) Trade receivables	-	-	-	-
(i) Other Tax assets (net) () Other for ax assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) () Other non-current assets (net) (net	(ii) Loans	244.28	245.25	254.40	255.37
(i) Deferred tax assets (net) (i) Other non-current assets Total Non-current assets (a) Inventories (b) Financial Liabilities (i) Irade Receivables (iii) Irade Payables (iii) Ira	(ii) Others	-	-	-	-
1,01,077	(h) Other Tax assets (net)	351.55	217.24	351.55	217.21
Total Non-current assets	(h) Deferred tax assets (net)	-	-	-	-
(2) Current Assets (a) Inventories (b) Financial Assets (c) Investments (ii) Trade Receivables (iii) Cash and eash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Others (vi) Others (vi) Others (vii) Cash and eash equivalents (viii) Others (viii) Cash and eash equivalents (viiii) Others (viiiii) Cash and eash equivalents (viiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	(i) Other non-current assets	1,617.07	2,194.42	1,617.07	2,194.42
(a) Inventories (b) Financial Assets (c) Financial Assets (d) Investments (e) Financial Assets (e) Financial Assets (e) Financial Assets (e) Investments (e) Financial Assets (e) Investments (e) Financial Assets (e) Financial Assets (e) Financial Assets (e) Financial Assets (e) Financial Liabilities (f)	Total Non-current assets	24,041.10	21,268.66	23,996.72	21,260.45
(a) Inventories (b) Financial Assets (c) Financial Assets (d) Investments (e) Financial Assets (e) Financial Assets (e) Financial Assets (e) Investments (e) Financial Assets (e) Investments (e) Financial Assets (e) Financial Assets (e) Financial Assets (e) Financial Assets (e) Financial Liabilities (f)					
(b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Others (vi) Others (vi) Others (vi) Others (vi) Others (vii) Others (vii) Others (vii) Others (viii) Cash and cash equivalents (vi) Others (vi) Others (vii) Others (viii) Others (viii) Others (viiii) Cash and cash equivalents (vii) Others (viiiii) Cash and cash equivalents (vii) Others (viiiiii) Cash and cash equivalents (viiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	(2) Current Assets				
(i) Investments (ii) Trade Receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (iv) Loans (v) Loans (v) Loans (v) Loans (v) Others (v) Loans (v) Others (v)	(a) Inventories	12,117.06	9,284.95	12,117.06	9,284.95
(ii) Trade Receivables (iii) Cash and cash equivalents (27.26 16.44 30.81 21.2 (iv) Bank balances other than (iii) above (117.97 126.90 117.97 126.90 (v) Loans (28.90.57 4.88 2.890.57 4.88 (28.90.57 4.88 (28.90.57 4.88 2.890.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.88 (28.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.60.85 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.60.85 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.60.85 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.87 1.460.87 3.20.25 (29.90.57 4.89.38 3.20.27 3.20.25 (29.90.57 4.89.38 3.20.27 3.20.25 (29.90.57 4.89.38 3.20.27 3.20.25 (29.90.57 4.89.38 3.20.27 3.20.25 (29.90.57 4.89.38 3.20.27 3.20.25 (29.90.57 4.89.38 3.20.27 3.20.25 (29.90.57 4.89.38 3.20.25 (29.20.25 4.89.48 3.20.25 (29.20.25 4.89.48 3.20.25 (29.20.25 4.89.48 3.20.25	(b) Financial Assets				
(iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Chors (vi) Chors (vi) Others (vi) Others (vii) Others (vi) Others (vi) Others (vi) Others (vi) Others (viii) Others (vi) Others (vi) Others (vi) Others (vi) Others (vii) Others (viiii) Others (viiiiii) Others (viiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	(i) Investments	-	-	-	-
117.97 126.90 127.91 126.90 117.97 126.90 127.91 126.90 117.97 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 126.90 127.91 1	(ii) Trade Receivables	16,083.06	12,179.58	16,084.49	12,180.93
(v) Loans (vi) Others 2,890.57 4.85 2,890.57 4.8 2,800.57 4.8 2,800.57 2,634 473.35 26.3 473.35 26.3 1,459.38 3,200.87 1,460.87 3,202.5 Total Current assets 1,459.38 3,200.87 1,460.87 3,202.5 Total Current Assets 33,168.65 24,839.93 33,175.12 24,847.7 Total Assets 57,209.75 46,108.59 57,171.84 46,108.2	(iii) Cash and cash equivalents	27.26	16.44	30.81	21.23
(vi) Others	(iv) Bank balances other than (iii) above	117.97	126.90	117.97	126.90
Cc Other current assets 1,459.38 3,200.87 1,460.87 3,202.5	(v) Loans	2,890.57	4.85	2,890.57	4.85
Total Current Assets	(vi) Others	473.35	26.34	473.35	26.34
Total Assets	(c) Other current assets	1,459.38	3,200.87	1,460.87	3,202.56
EQUITY AND LIABILITIES Equity	Total Current Assets	33,168.65	24,839.93	33,175.12	24,847.76
EQUITY AND LIABILITIES Equity	m		15 100 50		45 400 24
Equity Common C	Total Assets	57,209.75	46,108.59	57,171.84	46,108,21
Equity Common C	EQUITY AND LIABILITIES				
A Equity Share capital 1,956.84 1,955.27 1,956.84 1,955.27 1,956.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,955.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.84 1,255.27 1,256.85 32.22 2,269.74 1,256.85 32.22 2,269.74 1,256.85 32.22 2,275.95 1,256.85 32.22 2,275.95 1,256.85 1,256					
(b) Other Equity		1 956 84	1 955 27	1 956 84	1,955.27
Ce Non controlling interest - - 32.85 31.2					
Total Equity 24,643.90 20,246.49 24,689.43 20,279.99	* *		_		31.25
LIABILITIES (1) Non-current liabilities (a) Financial Liabilities (i) Lease liability 36.16 - - - -		24,643,90	20,246,49		20,279.90
(1) Non-current liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (net) Total Non Current Liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (net) Total Non Current Liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iiii) Other financial liabilities (iii) Other financial liabilities (iii) Other current liabilities (iii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiiii) Other current liabilities (iiiii) Other current liabilities (iiiiii) iiiiiiiiiiiiiiiiiiiiiiiiiii		,			
(1) Non-current liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (net) Total Non Current Liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (net) Total Non Current Liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iiii) Other financial liabilities (iii) Other financial liabilities (iii) Other current liabilities (iii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiiii) Other current liabilities (iiiii) Other current liabilities (iiiiii) iiiiiiiiiiiiiiiiiiiiiiiiiii					
(a) Financial Liabilities (i) Lease liability 36.16 (b) Provisions 32.02 22.86 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 22.8 32.02 32.02 32.03 32.02 22.8 32.02 32.03 32.03 32.02 32.03 32.03 32.03 32.02 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03 32.03					
(i) Lease liability (b) Provisions (c) Deferred tax liabilities (net) Total Non Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iii) Other financial liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iiii) Other current liabilities (iiii) Other current liabilities (iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	(1) Non-current liabilities				
(b) Provisions (c) Deferred tax hiabilities (net) Total Non Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from ther than Micro, Small and Medium Enterprises (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iii) Other funancial liabilities (iii) Other funancial liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iii) Other funancial liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iiii) Other current Liabilities (iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii					
(c) Deferred tax liabilities (net) Total Non Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other current Liabilities (iii) Other current liabilities (iii) Other current Liabilities (iiii) Other current Liabilities (iiiii) Other current Liabilities (iiiiii) Other current Liabilities (iiiiii) Other current Liabilities (iiiiii) Other current Liabilities (iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii			-	-	-
Total Non Current Liabilities	(b) Provisions	32.02	22.86	32.02	22.86
(2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iii) Other financial liabilities (iii) Other current liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iii) Other current Liabilities (iiii) Other current Liabilities (iiiiii) Other current Liabilities (iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii					925.02
(a) Financial Liabilities (i) Borrowings (ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions Total Current Liabilities (a) 9,871.16 17,566.79 9,871.16 17,566.79 9,871.16 17,566.79 9,871.16 17,566.79 102.6 11.91 102.6 102.6 103	Total Non Current Liabilities	677.68	945,81	646,12	947.88
(a) Financial Liabilities (i) Borrowings (ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises Total outstanding dues from other than Micro, Small and Medium Enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions Total Current Liabilities (a) 9,871.16 17,566.79 9,871.16 17,566.79 9,871.16 17,566.79 9,871.16 17,566.79 102.6 11.91 102.6 102.6 103	(2) (2) (3) (4)				
(i) Borrowings 9,871.16 17,566.79 9,871.16 17,566.7 (ii) Trade payables					
(ii) Trade payables Total outstanding dues from Micro, Small and Medium Enterprises 11.91 102.64 11.91 102.6 Total outstanding dues from other than Micro, Small and Medium Enterprises 20,275.10 6,261.58 20,227.05 6,222.8 (iii) Other financial liabilities 1,584.37 893.03 1,579.06 894.9 (b) Other current liabilities 91.20 55.76 92.68 56.7 (c) Provisions 54.43 36.49 54.43 36.4 Total Current Liabilities 31,888.17 24,916.29 31,836.29 24,880.4					
Total outstanding dues from Micro, Small and Medium Enterprises 11.91 102.64 11.91 102.64 10.266	· · · · · · · · · · · · · · · · · · ·	9,871.16	17,566.79	9,871.16	17,566.79
Enterprises 11.91 102.64 11.91 102.64 10.264					
Total outstanding dues from other than Micro, Small and Medium Enterprises 20,275.10 6,261.58 20,227.05 6,222.8	•				
Medium Enterprises 20,275.10 6,261.58 20,227.05 6,222.8 (iii) Other financial liabilities 1,584.37 893.03 1,579.06 894.9 (b) Other current liabilities 91.20 55.76 92.68 56.7 (c) Provisions 54.43 36.49 54.43 36.4 Total Current Liabilities 31,888.17 24,916.29 31,836.29 24,880.4		11.91	102.64	11.91	102.64
(iii) Other financial liabilities 1,584.37 893.03 1,579.06 894.9 (b) Other current liabilities 91.20 55.76 92.68 56.7 (c) Provisions 54.43 36.49 54.43 36.4 Total Current Liabilities 31,888.17 24,916.29 31,836.29 24,880.4				20.000	
(b) Other current liabilities 91.20 55.76 92.68 56.7 (c) Provisions 54.43 36.49 54.43 36.4 Total Current Liabilities 31,888.17 24,916.29 31,836.29 24,880.4					
(c) Provisions 54.43 36.49 54.43 36.4 Total Current Liabilities 31,888.17 24,916.29 31,836.29 24,880.4	· /				
Total Current Liabilities 31,888.17 24,916.29 31,836.29 24,880.4					
Total Equity and Liabilities 57,209.75 46,108.59 57,171.84 46,108.2	Total Current Liabilities	31,000.1/	24,910.29	31,030.29	24,000.43
	Total Equity and Liabilities	57,209.75	46,108.59	57,171.84	46,108.21

For Astec LifeSciences Limited

ASHOK VISHWANATH HIRENMATH

Ashok Hiremath Managing Director DIN:-00349345 Tuesday, 5th May, 2020, Mumbai

BURJIS Digitally signed by BURJIS TEHMURASP PARDIWALA Date: 2020.05.05 17:33:11 +05'30'

BSR&Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited.

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Astec LifeSciences Limited Company Limited (hereinafter referred to as the "Company") for the year ended 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

Astec LifeSciences Limited.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results (Continued)

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Astec LifeSciences Limited.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results (Continued)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

BURJIS Digitally signed by BURJIS TEHMURASP PARDIWALA Date: 2020.05.05 17:26:56+05'30'

Burjis Pardiwala

Partner r: 103595

Membership Number: 103595 UDIN: 20103595AAAABE9353

Mumbai 5 May 2020

BSR&Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Astec LifeSciences Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31 March 2020, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of report of other auditors on separate audited financial statements / financial information of the subsidiaries referred to in other matters paragraph below, the aforesaid consolidated annual financial results:

- a. include the annual financial results/ financial information of the following entities:
 - i. Behram Chemicals Private Limited
 - ii. Astec Europe SPRL
 - iii. Comercializadora Agricola Agroastrachem CIA LTDA
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Astec LifeSciences Limited

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Astec LifeSciences Limited

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results (Continued)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Astec LifeSciences Limited

Other Matters

- (a) The consolidated annual financial results include the audited financial results of a subsidiary, whose financial results reflect total assets (before consolidation adjustments) of Rs.103.34 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs.10.80 Lakhs and total net profit after tax (before consolidation adjustments) of Rs. 6.24 Lakhs and net cash inflows of Rs 0.00 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their independent auditors. The independent auditors' report on financial results of this entity has been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- (b) The consolidated annual financial results include the unaudited financial information of two subsidiaries, whose financial information reflect total assets (before consolidation adjustments) of Rs. 5.72 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs. 38.52 Lakhs and total net (loss) after tax (before consolidation adjustments) of Rs. (1.09) lakhs, and net cash (outflows) of Rs. (1.24) Lakhs for the year ended on that date, as considered in the consolidated annual financial results. These unaudited financial information have been furnished to us by the Board of Directors and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other auditors and the financial information certified by the Board of Directors.

(c) The consolidated annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

BURJIS Digitally signed by BURJIS TEHMURASP PARDIWALA Date: 2020.05.05 17:30:27 +05'30'

Burjis Pardiwala

Partner

Membership No: 103595 UDIN: 20103595AAAABF8002

Mumbai 5 May 2020

MACHINE READABLE AND SEARCHABLE FORMAT

A

Astec LifeSciences Limited

Corporate Identity Number: L99999MH1994PLC076236



Registered Office: Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra Website: www.asteels.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com
Statement of Audited Standalone Financial Results for the Quarter and Year ended 31st March. 2020

Rs. in Lakh (Except per Equity Share data)

		STANDALONE					
	n		Quarter Ended		Year Ended		
Sr. No	Particulars	31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19	
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
I	Revenue from Operations	18,018.43	12,483.36	13,375.79	52,222.09	43,090.12	
II	Other Income	524.15	393.09	574.04	1,193.25	1,110.07	
III	Total Income (I+II)	18,542.58	12,876.45	13,949.83	53,415.34	44,200.19	
IV	Expenses						
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18	
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)	
	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88	
	Finance costs	215.99	339.38	315.17	1,263.88	1,237.59	
	Depreciation and amortisation expense	616.37	579.15	547.46	2,322.38	1,934.06	
	Other expenses (Refer note 7)	1,705.55	1,639.10	1,252.09	6,893.41	4,990.03	
	Total expenses (IV)	14,581.46	11,317.33	11,932.07	47,287.92	38,620.86	
V	Profit / (loss) before exceptional items and tax (III - IV)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33	
VI	Exceptional Items	-	-	-	-	-	
VII	Profit / (loss) before tax (V + VI)	3,961.12	1,559.12	2,017.76	6,127.42	5,579.33	
VIII	Tax Expense:						
	(1) Current tax	1,047.74	402.48	472.87	1,605.78	1,528.88	
	(2) Deferred tax	(203.24)	(74.38)	244.91	(305.49)	442.22	
	(3) Tax for earlier years	-	15.60	30.05	79.94	39.63	
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60	
X	Profit / (loss) from discontinued operations	-	-	-	-	-	
XI	Tax expense of discontinued operations	-	-	-	-	-	
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	
XIII	Profit / (loss) for the period (IX + XII)	3,116.62	1,215.42	1,269.93	4,747.19	3,568.60	
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34	
	B (i) Items that will be reclassified to profit or loss	-	-	49.18	-	35.25	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)	
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	3,102.18	1,214.16	1,304.51	4,728.98	3,587.29	
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27	
XVII	Other Equity excluding Revaluation Reserve			, i	22,687.06	18,291.22	
3/3/117	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing &					· ·	
XVIII	discontinued operations) (non-annualised) :						
	(1) Basic (in Rs.)	15.94	6.21	6.50	24.27	18.26	
	(2) Diluted (in Rs.)	15.93	6.21	6.49	24.25	18.23	


Notes:

- 1 The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th May, 2020.
- 2 The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- 3 The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- 4 The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- 5 The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- 6 In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
 - In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- 7 Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- 8 Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

Ashok Hiremath Managing Director DIN :- 00349345 Tuesday, 5th May, 2020, Mumbai

Corporate Identity Number: L99999MH1994PLC076236





Statement of Audited Consolidated Financial Results for the Quarter and Year ended 31st March, 2020

Rs. in	Lakh (Exc	ept per E	quity Sha	ıre data)

CONSOLIDATED								
	Donatio 1		Quarter Ended		Year Ended			
Sr. No	Particulars	31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19		
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)		
I	Revenue from Operations	18,056.95	12,483.36	13,375.79	52,260.61	43,090.12		
П	Other Income	524.15	393.09	575.94	1,193.25	1,115.66		
III	Total Income (I+II)	18,581.10	12,876.45	13,951.73	53,453.86	44,205.78		
IV	Expenses							
	Cost of materials consumed	10,117.40	9,015.27	6,431.98	33,343.71	29,505.18		
	Purchase of Stock-in-Trade	37.07	-	-	37.07	-		
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,066.10	(1,002.22)	2,819.82	472.50	(1,555.88)		
	Employee benefits expense	860.05	746.65	565.55	2,992.04	2,509.88		
	Finance costs	214.88	338.27	315.17	1,259.43	1,237.59		
	Depreciation and amortisation expense	614.88	577.66	547.68	2,316.42	1,934.94		
	Other expenses (Refer note 7)	1,707.45	1,639.81	1,249.97	6,897.44	4,983.66		
	Total expenses (IV)	14,617.83	11,315.44	11,930.17	47,318.61	38,615.37		
V	Profit / (loss) before exceptional items and tax (III - IV)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41		
VI	Exceptional Items	-	-	-	-	-		
VII	Profit / (loss) before tax (V + VI)	3,963.27	1,561.01	2,021.56	6,135.25	5,590.41		
VIII	Tax Expense:		400.00	.=				
	(1) Current tax	1,048.07	402.90	473.69	1,607.40	1,530.88		
	(2) Deferred tax	(203.01)	(74.22)	245.20	(304.80)	442.94		
177	(3) Tax for previous years	2 110 21	15.60	30.05	79.94	40.05 3,576.54		
IX X	Profit / (loss) for the period from continuing operations (VII-VIII)	3,118.21	1,216.73	1,272.62	4,752.71	3,5/6.54		
XI	Profit / (loss) from discontinued operations Tax expense of discontinued operations		-	-	-	-		
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-		
XIII	Profit / (loss) for the period (IX + XII)	3,118.21	1,216.73	1,272.62	4,752.71	3,576.54		
XIV	Other Comprehensive Income	3,110.21	1,210.73	1,2/2.02	4,732.71	3,370.34		
7111	A (i) Items that will not be reclassified to profit or loss	(19.31)	(1.68)	3.80	(24.34)	(6.70)		
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.87	0.42	(1.33)	6.13	2.34		
	B (i) Items that will be reclassified to profit or loss	1.26	(0.73)	49.15	1.15	36.01		
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	(17.07)	-	(12.20)		
	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit			\ /				
XV	/ (loss) and Other Comprehensive Income for the period)	3,105.03	1,214.74	1,307.17	4,735.65	3,595.99		
XVI	Net Profit/(loss) attributable to:							
	- Owners	3,117.61	1,216.39	1,271.78	4,751.11	3,573.68		
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86		
	Total Comprehensive Income attributable to:							
	- Owners	3,104.43	1,214.40	1,306.33	4,734.05	3,593.13		
	- Non controlling interests	0.60	0.34	0.84	1.60	2.86		
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,956.84	1,956.56	1,955.27	1,956.84	1,955.27		
XVIII					22,699.74	18,293.38		
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing &							
AIA	discontinued operations) (non-annualised) :							
	(1) Basic (in Rs.)	15.94	6.22	6.50	24.29	18.28		
	(2) Diluted (in Rs.)	15.93	6.21	6.50	24.27	18.26		

Notes:

- 1 The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 5th
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- 3 The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- 4 The figures for the Quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between audited figures in respect of the full Financial Year and the published unaudited Year To Date figures upto the end of the third Quarter of the relevant Financial Year.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/each for the Financial Year ended 31st March, 2020, subject to approval of the Shareholders at the ensuing 26th Annual General Meeting of the Company.
- 6 In March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption. In assessing the recoverability of receivables and other financial assets, the company has considered internal and external information upto the date of approval of
 - these financial results. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely monitor any material changes to future economic conditions.
- 7 Other expenses for "Year ended 31st March, 2020" includes Rs.620.09 Lakhs in respect of a classification error of export incentives claimed in earlier years for certain products exported by the Company.
- Effective 1st April, 2019, the Company has adopted Ind-AS 116 "Leases" using modified retrospective approach. This has resulted in recognizing right of use assets and lease liability as on 1st April, 2019. The adoption of the standard did not have any material impact on the financial results.

For Astec LifeSciences Limited

Ashok Hiremath Managing Director DIN :- 00349345 Tuesday, 5th May, 2020, Mumbai



Astec LifeSciences Limited Corporate Identity Number: L99999MH1994PLC076236




Registered Office: Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra Website: www.astecls.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Cash Flows for the Year ended 31st March, 2020

(Rs. in Lakh)

	STANDA		CONSOLIE	
D. I. DOWN CHAIR A DO		Year Ended		ded
<u>PARTICULARS</u>	31-Mar-20	31-Mar-19	31-Mar-20	31-Mar-19
	(Audited)	(Audited)	(Audited)	(Audited)
Cash flow from operating activities				
Profit before tax	6,127.42	5,579.33	6,135.25	5,590.
Adjustments for	,,,,,,,,	,,,,,,,,,,	***************************************	-,
Depreciation and amortisation expense	2,321.89	1,934.06	2,316.42	1,934
Interest income	(26.56)	(36.28)	(26.56)	(36
Finance cost	1,263.88	1,237.59	1,259.43	1,237
Unrealised foreign exchange (gain)/loss	142.74	(189.76)	143.89	(189
Loss allowance	31.14	3.58	31.14	3
Loss/(Gain) on sale of property, plant and equipment	17.96	(0.04)	17.96	(0
Bad debts / advances written off	- 17.50	242.54	-	242
Employee stock options expense	5.55	16.35	5.55	16
Net loss / (Gain) on lease modification	0.48	10.55	5.55	10
Sundry balances written back	0.40	(174.75)	_	(174
Sundry balances written back	3,757.08	3,033.29	3,747.83	3,034
		·		
Operating Profit Before Working Capital Changes	9,884.50	8,612.62	9,883.08	8,625
Change in operating assets and liabilities (Increase)/Decrease in trade receivables	(2.427.45)	(102.00)	(2, 427, 52)	(102
	(3,437.45)	(102.89)	(3,437.53)	(102
(Increase)/Decrease in loans	1.77	(52.85)	1.77	(52
(Increase)/Decrease in other financial assets-current	(430.63)	91.08	(430.63)	91
(Increase)/Decrease in other current assets	1,741.49	(431.51)	1,741.69	(431
(Increase)/Decrease in inventories	(2,832.11)	(1,437.12)	(2,832.11)	(1,437
(Increase)/Decrease in other non-current assets	38.40	(12.77)	38.40	(12
Increase/(Decrease) in trade payables	13,124.53	(3,514.01)	13,115.25	(3,554
Increase/(Decrease) in other financial liabilities	547.45	19.37	547.15	52
Increase/(Decrease) in other current liabilities	35.44	8.99	35.91	2
Increase/(Decrease) in provisions	2.76	(7.90)	2.76	(7
Cash generated from operations	18,676.15	3,173.01	18,665.74	3,171
Direct Taxes paid (net of refunds received)	(1,820.03)	(1,640.51)	(1,821.68)	(1,642
Net cash inflow / (outflow) operating activities	16,856.12	1,532.50	16,844.06	1,528
Cash flow from investing activities				
Acquisition of property, plant and equipment & cwip	(4,529.40)	(5,277.54)	(4,529.40)	(5,277
Proceeds from sale of property, plant and equipment	15.75	1.61	15.75	1
Intercorporate deposits given	(2,886.52)	-	(2,886.52)	
Deposits redeemed / (placed)	10.98	(10.27)	10.98	(10
Interest received	8.12	36.28	8.12	36
Net cash inflow / (outflow) investing activities	(7,381.07)	(5,249.92)	(7,381.06)	(5,249
	T	\Box		
Cash flow from financing activities	(7.020.72)	5 272 02	(7,920,72)	£ 0.70
Proceeds / (Repayment) of borrowings (net)	(7,830.73)	5,272.93	(7,830.73)	5,272
Proceeds from issue of shares	21.96	27.60	21.96	27
Payment of lease liabilities	(10.80)	(1.007.50)	(1.201.02)	(1.005
Finance cost	(1,291.03)	(1,237.59)	(1,291.03)	(1,237
Divid 1 11/2 1 1 1 1 1 2 1 2 2 2 2 2 2 2 2 2	(353.63)	(353.45)	(353.63)	(353
Dividend paid to company's shareholders (including Dividend	(000.00)			
Dividend paid to company's shareholders (including Dividend Distribution Tax) Net cash inflow (outflow) from financing activities	(9,464.23)	3,709.49	(9,453.43)	3,709
Distribution Tax) Net cash inflow (outflow) from financing activities	(9,464.23)	Ź		3,709
Distribution Tax) Net cash inflow (outflow) from financing activities Net increase / (decrease) in cash and cash equivalents	(9,464.23) 10.82	(7.93)	9.58	(11
Distribution Tax) Net cash inflow (outflow) from financing activities	(9,464.23)	Ź		





Registered Office: Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai-400079, Maharashtra
Website: www.astecls.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com
Statement of Assets and Liabilities as at 31st March, 2020

	STAND	ALONE	CONSO	(Rs. in Lakh)	
PARTICULARS	As at	As at	As at As at		
MITTELLAND	31st March, 2020	31st March, 2019	31st March, 2020	31st March, 2019	
ASSETS	(Audited)	(Audited)	(Audited)	(Audited)	
ASSETS (1) Non-current assets					
(a) Property, Plant and Equipment	17,747,43	16,457.64	17,772.40	16,488.23	
(b) Capital work-in-progress	2,211.22	1,863.24	2,211.22	1,863.24	
(c) Investment property	_ ´ _	-	´ -	-	
(c) Right of use	1,463.75	-	1,433.17	-	
(d) Other Intangible assets	156.86	206.71	156.86	206.71	
(e) Intangible assets under development	199.52	34.74	199.52	34.74	
(g) Biological Assets other than bearer plants	40.00	-	-	-	
(f) Investments in Subsidiaries (g) Financial Assets	48.89	48.89	-	-	
(i) Investments	0.53	0.53	0.53	0.53	
(ii) Trade receivables	-	-	-	-	
(ii) Loans	244.28	245.25	254.40	255.37	
(ii) Others	-	-	-	-	
(h) Other Tax assets (net)	351.55	217.24	351.55	217.21	
(h) Deferred tax assets (net)					
(i) Other non-current assets	1,617.07	2,194.42	1,617.07	2,194.42	
Total Non-current assets	24,041.10	21,268.66	23,996.72	21,260.45	
(2) Current Assets					
(a) Inventories	12,117.06	9,284.95	12,117.06	9,284.95	
(b) Financial Assets	12,117.00	9,204.93	12,117.00	9,204.93	
(i) Investments	_	_	_	_	
(ii) Trade Receivables	16,083.06	12,179.58	16,084.49	12,180.93	
(iii) Cash and cash equivalents	27.26	16.44	30.81	21.23	
(iv) Bank balances other than (iii) above	117.97	126.90	117.97	126.90	
(v) Loans	2,890.57	4.85	2,890.57	4.85	
(vi) Others	473.35	26.34	473.35	26.34	
(c) Other current assets	1,459.38	3,200.87 24,839.93	1,460.87	3,202.56 24,847.76	
Total Current Assets	33,168.65	24,839.93	33,175.12	24,847.70	
Total Assets	57,209.75	46,108.59	57,171.84	46,108.21	
EQUITY AND LIABILITIES					
Equity					
(a) Equity Share capital	1,956.84	1,955.27	1,956.84	1,955.27	
(b) Other Equity	22,687.06	18,291.22	22,699.74	18,293.38	
(c) Non controlling interest	-	-	32.85	31.25	
Total Equity	24,643.90	20,246.49	24,689.43	20,279.90	
<u>LIABILITIES</u>					
(1) Non-current liabilities					
(a) Financial Liabilities (i) Lease liability	36.16				
(b) Provisions	32.02	22.86	32.02	22.86	
(c) Deferred tax liabilities (net)	609.50	922.95	614.10	925.02	
Total Non Current Liabilities	677.68	945.81	646.12	947.88	
(2) Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings	9,871.16	17,566.79	9,871.16	17,566.79	
(ii) Trade payables					
Total outstanding dues from Micro, Small and Medium	11.01	102.51	11.01	102 64	
Enterprises Total outstanding dues from other than Micro Small and	11.91	102.64	11.91	102.64	
Total outstanding dues from other than Micro, Small and Medium Enterprises	20,275.10	6,261.58	20,227.05	6,222.80	
(iii) Other financial liabilities	1,584.37	893.03	1,579.06	894.94	
(b) Other current liabilities	91.20	55.76	92.68	56.77	
(c) Provisions	54.43	36.49	54.43	36.49	
Total Current Liabilities	31,888.17	24,916.29	31,836.29	24,880.43	
Total Equity and Liabilities	57,209.75	46,108.59	57,171.84	46,108.21	

For Astec LifeSciences Limited

Ashok Hiremath Managing Director DIN :- 00349345

Tuesday, 5th May, 2020, Mumbai

BSR&Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited.

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Astec LifeSciences Limited Company Limited (hereinafter referred to as the "Company") for the year ended 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

Astec LifeSciences Limited.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results (Continued)

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Astec LifeSciences Limited.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results (Continued)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants
Firm's Registration No: 101248W/W-100022

Burjis Pardiwala

Partner

Membership Number: 103595 UDIN: 20103595AAABE9353

Mumbai 5 May 2020

BSR&Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Independent Auditors' Report

To The Board of Directors of Astec LifeSciences Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Astec LifeSciences Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31 March 2020, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of report of other auditors on separate audited financial statements / financial information of the subsidiaries referred to in other matters paragraph below, the aforesaid consolidated annual financial results:

- a. include the annual financial results/ financial information of the following entities:
 - i. Behram Chemicals Private Limited
 - ii. Astec Europe SPRL
 - iii. Comercializadora Agricola Agroastrachem CIA LTDA
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Astec LifeSciences Limited

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Astec LifeSciences Limited

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results (Continued)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Astec LifeSciences Limited

Other Matters

- (a) The consolidated annual financial results include the audited financial results of a subsidiary, whose financial results reflect total assets (before consolidation adjustments) of Rs.103.34 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs.10.80 Lakhs and total net profit after tax (before consolidation adjustments) of Rs. 6.24 Lakhs and net cash inflows of Rs 0.00 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their independent auditors. The independent auditors' report on financial results of this entity has been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- (b) The consolidated annual financial results include the unaudited financial information of two subsidiaries, whose financial information reflect total assets (before consolidation adjustments) of Rs. 5.72 Lakhs as at 31 March 2020, total revenue (before consolidation adjustments) of Rs. 38.52 Lakhs and total net (loss) after tax (before consolidation adjustments) of Rs. (1.09) lakhs, and net cash (outflows) of Rs. (1.24) Lakhs for the year ended on that date, as considered in the consolidated annual financial results. These unaudited financial information have been furnished to us by the Board of Directors and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other auditors and the financial information certified by the Board of Directors.

(c) The consolidated annual financial results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

Burjis Pardiwala

Partner

Membership No: 103595 UDIN: 20103595AAAABF8002

Mumbai 5 May 2020